Goldberg Manijeh, Manzi Aaron, Aydin Erkin, Singh Gurtej, Khoshkenar Payam, Birdi Amritpreet, LaPorte Brandon, Krauskopf Alejandro, Powell Geralle, Chen Julie, Langer Robert
Massachusetts Institute of Technology , Cambridge, MA 02139.
Wellesley College , Department of Biology, Wellesley, MA 02481.
J Nanotechnol Eng Med. 2014 Nov;5(4):0409051-4090511. doi: 10.1115/1.4030899.
The following work describes the development of a novel noninvasive transmucosal drug delivery system, the chitosan sponge matrix (CSM). It is composed of cationic chitosan (CS) nanoparticles (NPs) that encapsulate cisplatin (CDDP) embedded within a polymeric mucoadhesive CS matrix. CSM is designed to swell up when exposed to moisture, facilitating release of the NPs via diffusion across the matrix. CSM is intended to be administered topically and locally to mucosal tissues, with its initial indication being oral cancer (OC). Currently, intravenous (IV) administered CDDP is the gold standard chemotherapeutic agent used in the treatment of OC. However, its clinical use has been limited by its renal and hemotoxicity profile. We aim to locally administer CDDP via encapsulation in CS NPs and deliver them directly to the oral cavity with CSM. It is hypothesized that such a delivery device will greatly reduce any systemic toxicity and increase antitumor efficacy. This paper describes the methods for developing CSM and maintaining the integrity of CDDP NPs embedded in the CSM.
以下工作描述了一种新型非侵入性经粘膜给药系统——壳聚糖海绵基质（CSM）的研发情况。它由阳离子壳聚糖（CS）纳米颗粒（NPs）组成，这些纳米颗粒包裹着嵌入聚合物粘膜粘附性CS基质中的顺铂（CDDP）。CSM设计为在接触水分时膨胀，通过扩散穿过基质促进NP的释放。CSM旨在局部给药于粘膜组织，其初始适应症为口腔癌（OC）。目前，静脉注射（IV）的CDDP是用于治疗OC的金标准化疗药物。然而，其临床应用受到肾毒性和血液毒性的限制。我们旨在通过将CDDP包裹在CS NPs中并使用CSM将其直接递送至口腔进行局部给药。据推测，这种给药装置将大大降低任何全身毒性并提高抗肿瘤疗效。本文描述了开发CSM以及维持嵌入CSM中的CDDP NPs完整性的方法。
